Methods for detecting oncofetal fibronectin
First Claim
1. A method for classifying the level of oncofetal fibronectin protein in a cervicovaginal sample, comprising:
- measuring the amount of oncofetal fibronectin protein in said sample taken from an asymptomatic patient at less than 20 weeks gestation;
comparing the amount of oncofetal fibronectin protein in said sample to a threshold level of 150 ng/ml; and
classifying the amount of oncofetal fibronectin protein in said sample according to said threshold level, whereby classification of oncofetal fibronectin protein molecule in the sample above said threshold identifies a higher risk of preterm delivery.
5 Assignments
0 Petitions
Accused Products
Abstract
Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronection for selection of concepti are provided.
-
Citations
1 Claim
-
1. A method for classifying the level of oncofetal fibronectin protein in a cervicovaginal sample, comprising:
- measuring the amount of oncofetal fibronectin protein in said sample taken from an asymptomatic patient at less than 20 weeks gestation;
comparing the amount of oncofetal fibronectin protein in said sample to a threshold level of 150 ng/ml; and
classifying the amount of oncofetal fibronectin protein in said sample according to said threshold level, whereby classification of oncofetal fibronectin protein molecule in the sample above said threshold identifies a higher risk of preterm delivery.
- measuring the amount of oncofetal fibronectin protein in said sample taken from an asymptomatic patient at less than 20 weeks gestation;
Specification